glp-1 agonist alzheimer's Frontiers Glucagon like peptide-1 (GLP-1) likes
Description
It happens with bariatric surgery, extreme caloric restriction, and other pharmacological weight loss interventions
thus, they are an attractive therapeutic option for patients with type 2 diabetes, especially those with existing cardiovascular disease or at high risk for those complications
It is administered once daily by subcutaneous injection
In addition, regulatory and quality personnel are needed
Until prices drop or value improves, broader public coverage remains a tough sell
This scenario highlights the tension between ensuring drug availability and maintaining rigorous safety standards
